Streamline Health(STRM) - 2025 Q1 - Quarterly Report

Revenue Performance - For the three months ended April 30, 2024, total revenues decreased by $1,002,000, or 19%, to $4,330,000 compared to $5,332,000 for the same period in 2023[113] - Revenue from Software as a Service (SaaS) decreased by $452,000, or 14%, primarily due to a client non-renewal that contributed to a $944,000 decrease[113] - Revenue from maintenance and support decreased by $267,000, or 23%, compared to the same period in the prior year[115] - Revenue from professional fees and licenses decreased by $283,000, or 28%, compared to the same period in the prior year[116] - The Company anticipates maintenance and support revenue will decline in fiscal 2024 due to expected contract non-renewals and limited new sales[115] Cost Management - The Company expects to realize approximately $5,800,000 in annualized cost savings from a Strategic Restructuring that included a reduction of 26 employees, or 24% of the workforce[111] - Cost of sales for the three months ended April 30, 2024, decreased by $509,000, or 18%, to $2,277,000 compared to $2,786,000 for the same period in 2023[120] - General and administrative expenses decreased by $373,000, or 14%, to $2,246,000 for the three months ended April 30, 2024[128] - Sales and marketing expenses decreased by $276,000, or 23%, to $946,000 for the three months ended April 30, 2024[128] - Research and development expenses for the three months ended April 30, 2024, decreased by $590,000 (35%) to $1,111,000 compared to $1,701,000 in the prior year period[130] - Capitalized research and development costs for the same period decreased by $157,000 (39%) to $247,000 from $404,000[131] Financial Position - Cash and cash equivalents increased to approximately $3,979,000 as of April 30, 2024, from $3,190,000 at January 31, 2024[147] - The company has a term loan facility with a maximum principal amount of $10,000,000, with interest rates tied to the Prime Rate plus 1.5%[148] - As of April 30, 2024, the company was in compliance with all debt covenants under the Second Amended and Restated Loan Agreement[149] - Significant cash obligations include a term loan of $8,839,000 and notes payable of $3,587,000 as of April 30, 2024[151] Net Loss and Cash Flow - Net loss for the three months ended April 30, 2024, was $2,739,000, a slight improvement from a net loss of $2,901,000 in the same period last year[153] - Net cash used in operating activities increased to $1,199,000 for the three months ended April 30, 2024, compared to a cash provided of $126,000 in the prior year[153] - Cash used in investing activities was $232,000 for the three months ended April 30, 2024, down from $433,000 in the same period last year, primarily due to capitalized software development costs[154] - Proceeds from notes payable amounted to $4,400,000 for the three months ended April 30, 2024, compared to a payment of $125,000 in the same period last year[155] - Net cash provided by financing activities was $2,220,000 for the three months ended April 30, 2024, compared to a cash used of $304,000 in the prior year[155] Adjusted EBITDA and Other Income - Adjusted EBITDA improved to a loss of $703,000 for the three months ended April 30, 2024, compared to a loss of $1,337,000 in the prior year, resulting in an Adjusted EBITDA margin of (16%) versus (25%)[145] - Interest expense increased by $217,000 (88%) to $465,000 for the three months ended April 30, 2024, compared to $248,000 in the prior year[133] - Total other income decreased by $637,000 (430%) to a loss of $489,000 for the three months ended April 30, 2024, from income of $148,000 in the prior year[133] - The company recorded an income tax expense of $53,000 for the three months ended April 30, 2023, while no tax benefit was recorded for the same period in 2024[136] - Non-cash adjustments to net loss were $1,795,000 for the three months ended April 30, 2024, compared to $1,306,000 in the prior year[153] Future Expectations - The company expects continued capitalizable projects associated with its flagship products, although the rate of capitalization may decrease due to the Strategic Restructuring announced in October 2023[154] - The company anticipates the acquisition earnout liability to be settled by October 31, 2024, reflecting the cash balance expected to be paid out[152]